Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1 antibodies) can enhance antitumor responses and delay tumor growth [9, 10]. This evidence concerns the gene PDCD1 and neoplasm.